Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038545
Status:
COMPLETED
Last Update Posted:
2018-10-30
First Post:
2002-05-31
Brief Title:
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD01 Support For Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
For patients with relapsed and refractory aggressive non-Hodgkins lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None